Genetic Finding May Lead To Targeted Therapy For Neuroblastoma
Researchers have identified a genetic glitch that could lead to development of neuroblastoma, a deadly form of cancer that typically strikes children under 2.
Two University of Florida scientists are part of the multicenter team of researchers that made the discovery, which could pave the way for better treatments that target the disease, according to findings published Wednesday in the journal Nature.
“What makes our study so important is that although neuroblastoma accounts for 7 percent of childhood cancers, it is responsible for 15 percent of deaths in children with cancer,” said Wendy London, Ph.D., a research associate professor of epidemiology, biostatistics and health policy research at the UF College of Medicine and a member of the UF Shands Cancer Center. “This paper adds yet another gene in the pathway that could lead to tumorigenesis (tumor formation) of neuroblastoma.”
Neuroblastoma forms in developing nerve cells, with tumors most often found on a child’s adrenal gland. It’s the most common form of cancer in babies and the third most common childhood cancer, according to the American Cancer Society.
Led by John J. Maris, M.D., director of the Cancer Center at The Children’s Hospital of Philadelphia, researchers performed what’s known as a genome-wide association study to uncover errors in DNA that could be associated with neuroblastoma.
To do this, researchers analyzed the genetic makeup of 846 patients with neuroblastoma, whose samples were derived from the Children’s Oncology Group Neuroblastoma Tumor Bank, and 803 healthy patients in a control group.
On the basis of their initial findings, the researchers performed a second validation analysis, pinpointing that a glitch called a “copy number variation” in a single chromosome is associated with neuroblastoma. Copy number variation has to do with the gain, loss or duplication of snippets of DNA.
“This is part of series of papers that creates the bigger picture, an understanding of the genetic mechanisms that lead to neuroblastoma,” said London, the principal investigator for the Children’s Oncology Group Statistics and Data Center at UF. “We are searching for genetic targets to treat with therapy.”
The researchers reported additional genetic links in Nature Genetics in May. The team discovered that on the gene called BARD1, six single-nucleotide polymorphisms “” variations in tiny pieces of DNA “” were also associated with neuroblastoma.
“Only two years ago we had very little idea of what causes neuroblastoma,” said Maris, who led both studies. “Now we have unlocked a lot of the mystery of why neuroblastoma arises in some children and not in others.”
Although neuroblastoma is one of the more common childhood cancers, it is relatively rare overall when compared with more common adult cancers, which has proved to be a challenge for researchers trying to uncover its causes, said Peter Zage, M.D., Ph.D., an assistant professor of pediatrics at the Children’s Cancer Hospital at the University of Texas M.D. Anderson Cancer Center.
“Dr. Maris’ group has been able to collect a relatively large number of cases for a neuroblastoma study and so has been able to identify these genetic variations and specific genes to provide us with some new avenues for therapy that we probably would not have been able to identify looking at the smaller cohorts of patients we each see at our individual institutions. In that sense, it’s certainly an amazing leap forward in our understanding of the disease.”
The discovery does hold promise for developing treatments, but London cautions that these potential “targeted therapies” won’t work on all neuroblastoma patients. Not all neuroblastoma patients have this particular genetic anomaly, and not all children with this anomaly will develop neuroblastoma. Development of neuroblastoma is complicated and can occur because of multiple reasons, arising after a complex chain of events, London said.
“What’s amazing is there are so many different ways for tumorigenesis to occur,” London said. “That’s the reason it is so hard to treat and cure cancer, or even to understand why it happens and how it happens.”
All the researchers involved in the study are members of the Children’s Oncology Group, the only National Institutes of Health/National Cancer Institute pediatric cancer cooperative group. The group performs clinical trials, collects specimens and performs statistical analysis related to pediatric cancers. UF is one of three institutions with a COG Statistics and Data Center, where study design, data collection and statistical analysis for COG research occurs.
On The Net: